Forte Biosciences (NASDAQ:FBRX Get Rating) and Kezar Life Sciences (NASDAQ:KZR Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability...

Forte Biosciences, Inc. (NASDAQ:FBRX Get Rating) was the recipient of unusually large options trading on Wednesday. Traders purchased 30,205 call options on the company. This represents an increase of 1,663% compared to the typical volume of 1,713 call options. Forte Biosciences Trading Up 2...

Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases today announced the issuance of an equity inducement award as required by the Nasdaq Stock Market Rules. In accordance with NASDAQ Listing Rule 5635(c)(4), the Compensation...

Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases announces that Dr. Hubert Chen, MD has joined the company as Chief Scientific Officer and President. Dr. Chen is a very accomplished drug development scientist and physician and...

Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases, today announced first quarter 2022 results and provided a business update. Following a very extensive process by our Board, the management team and external advisors, Forte is...